Inhalers to be administered to patients at risk of Covid in the context of a major trial

by



[ad_1]



text: MailOnline logo


© Provided by Daily Mail
MailOnline Logo

A steroid in inhalers is added to a key trial looking for drugs that prevent mild cases of Covid-19 in vulnerable people from deteriorating to the point of hospitalization.

The drug, called budesonide, is the fourth drug to appear in the Principle trial. Two antibiotics, called azithromycin and doxycycline, are also being studied.

Donald Trump’s controversial antimalarial drug hydroxychloroquine was originally part of Principle but was suspended in May.

Budesonide has no known side effects associated with short-term use, is easy to make and inexpensive, researchers say, making it an ideal candidate.

Scroll down the video



diagram, text: A steroid in inhalers is added to a key trial looking for drugs that prevent mild cases of Covid-19 in vulnerable people from deteriorating to the point of hospitalization. Drug, called budesonide, is fourth drug to appear in Principle trial


© Provided by Daily Mail
A steroid in inhalers is added to a key trial looking for drugs that prevent mild cases of Covid-19 in vulnerable people from deteriorating to the point of hospitalization. Drug, called budesonide, is fourth drug to appear in Principle trial

Principle’s main goal is to find treatments that can be taken in the early days of a coronavirus infection and to stop it in its tracks, thus avoiding serious symptoms.

It is managed by the University of Oxford and funded by the UK government through UKRI and the Department of Health and Welfare.

Researchers currently have more than 2,000 volunteers for the study and are actively seeking to participate.

Only people who have symptoms of Covid-19 (fever, cough, or loss of smell) and who are over 50 and have specific health problems, or who are over 65, can participate in the study. .

Gallery: How vaccines are made and approved in the United States (Stacker)

a hand holding a blue object: COVID-19 and its many impacts on the lives of almost everyone on the planet have brought vaccines to the fore - if a suitable vaccine can be found and widely distributed, then life could may -being to resume a semblance of normality. All over the world, people are eagerly awaiting information about vaccine trials from companies such as Pfizer, Moderna and AstraZeneca. There have already been some promising developments. On November 16, Moderna released the results of a study that showed its vaccine to have a 94% effectiveness rate. Although the results of their Phase 3 trial in 30,000 people have not yet been released, the researchers said the results show the vaccine to be safe and effective. On November 18, Pfizer and its partner BioNTech announced the completion of its Phase 3 study (which began July 27) and determined that their vaccine is 95% effective. Pfizer and BioNTech will submit an emergency use clearance request to the FDA as soon as possible and plan to share their data with global regulatory agencies. On November 23, AstraZeneca also published the first results of its Phase 3 vaccine trial, conducted in partnership with the University of Oxford. AstraZeneca's vaccine has so far demonstrated an average efficacy rate of 70% - although not as impressive as Pfizer and Moderna, that rate still meets FDA clearance requirements. News from the three companies has given people hope that the SARS-CoV-2 virus that causes COVID-19 can eventually be controlled. However, there is also a distrust of vaccines and often a lack of understanding of how they are created, how they are tested, and how safe they are. If people don't trust the vaccine then people won't take it, and the pandemic could last longer. Part of this lack of confidence stems from a lack of information or misinformation. In order to demystify vaccines and the vaccine manufacturing and approval process in the United States, Stacker consulted with the Food & Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and other health sources. public to better understand and explain vaccines to the general public. After going through these authoritative sources of health information, Stacker identified some key terms to help readers better understand vaccine types and how they work, and then listed the many steps involved in creating, approving, and the distribution of new vaccines in the United States. then created a list of 30 key terms and steps, showing how intensive and precise the vaccine creation and approval process is, and ultimately that vaccines are safe and effective tools in disease control. You might also like: States with the highest COVID-19 infection rates

The pre-existing health conditions necessary to qualify 50-64 year olds are: a weakened immune system due to serious illness or medication (e.g. chemotherapy), heart disease or high blood pressure, asthma or lung disease, diabetes, liver disease, stroke or neurological problem, BMI of 35 or more.

Each participant receives either one of the drugs or just standard treatment – the control group.

Patients randomly assigned to the budesonide cohort will receive an inhaler and will be required to take two puffs twice daily for 14 days, with each puff providing a dose of 400 micrograms.

Professor Chris Butler, head of the Principle trial, said: ‘Budesonide is a relatively inexpensive, safe and easy to administer drug for respiratory conditions that may have a role to play in the treatment of Covid-19.

“It is only by recruiting volunteers into a randomized controlled trial like Principle that we can assess whether there are obvious advantages or disadvantages associated with potential treatments like budesonide.

“ We need a lot more volunteers to participate in the trial in order to get the answers we really need to keep people with Covid-19 from being released from the hospital.

“Like vaccines and preventive measures, treatments have an important role to play in minimizing the burden of this disease on society.

Experts hope that budesonide may be successful because other similar drugs, known as corticosteroids, reduce the number of ACE2 receptors on the surface of cells in the human airways.

ACE2 receptors are known to be the way the coronavirus infects human cells and reducing the amount of receptors may be a viable way to block viral entry.

Professor Richard Hobbs, Co-Director of Principle, said: “ We are constantly evaluating different treatments that might be suitable to help people with Covid-19 recover at home without needing to go to the hospital.

“We know from hospital-based trials, like Recovery, that intravenous treatment with dexamethasone corticosteroids can reduce mortality in patients already in hospital.

‘If we find budesonide to be an effective way to treat Covid-19 disease and prevent hospitalization, it could be quickly rolled out across the UK after regulatory approval. ”

Why patients with diabetes or Covid-19 heart disease are more likely to die

Cholesterol can help the coronavirus infect human cells by acting like a taxi service, new lab studies show.

The results may explain why people with metabolic disorders such as diabetes and cardiovascular disease, who often have high cholesterol levels, constitute a disproportionate number of patients who develop severe symptoms of Covid-19.

Researchers have found that SARS-CoV-2, the virus that causes Covid-19, can stick to cholesterol molecules as they bind to their normal cellular receptor, called SR-B1.

This helps position the pathogen so that its spike protein can bind to the ACE2 receptor, allowing it to infect the cell.

A study published in Nature Metabolism by researchers at the Chinese Academy of Military Medical Sciences examined the role of “ good ” cholesterol, also known as high density lipoprotein (HDL), in coronavirus infection .

The study looked specifically at the SR-B1 receptor, which connects to cholesterol molecules and is found on cells throughout the human body, including the lungs, where the coronavirus targets.

According to the study, SARS-CoV-2 cannot directly harness this receptor, but it can take advantage of the process of connecting cholesterol to SR-B1 to infiltrate cells.

Read more

[ad_2]

Source link